NCT07910435
Polatuzumab Vedotin, Mosunetuzumab, and Acalabrutinib for the Treatment of Mantle Cell Lymphoma, PAcMan Trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (6)
Show 1 moreShow less
Arms and interventions
INDUCTION: Patients receive polatuzumab vedotin IV over 30-90 minutes on day 1 of cycles 1-6, mosunetuzumab SC on days 1, 8, and 15 of cycle 1 and on day 1 of cycles 2-17, and acalabrutinib PO BID on days 1-21 of cycles 1-17. Cycles repeat every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients who achieve less than PR discontinue study. Standard risk patients who achieve CR proceed to surveillance. Responding high-risk patients and responding standard risk patients who fail to achieve CR proceed to maintenance. MAINTENANCE: Patients receive mosunetuzumab SC on day 1 of each cycle and acalabrutinib PO BID on days 1-56 of each cycle. Cycles repeat every 56 days for up to 12 cycles (cycles 18-29) in the absence of disease progression or unacceptable toxicity. Patients undergo collection of blood samples, FDG PET/CT, and core biopsy (optional) throughout the trial and undergo BMA and BMB at screening (optional) and on study.
Drugs: Polatuzumab Vedotin, Acalabrutinib
Biologicals: Mosunetuzumab
Procedures: Bone Marrow Biopsy, Core Biopsy, FDG-Positron Emission Tomography and Computed Tomography Scan, Neurologic Examination, Biospecimen Collection, Bone Marrow Aspiration
Other: Patient Observation
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States